Nov 4, 2024 8:00 am EST bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
Oct 30, 2024 8:00 am EDT bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
Oct 21, 2024 10:45 am EDT bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
Oct 18, 2024 12:45 pm EDT bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
Oct 16, 2024 8:00 am EDT bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
Oct 10, 2024 8:00 am EDT bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
Oct 9, 2024 8:00 am EDT bioAffinity Technologies Awarded U.S. Federal Supply Schedule Contract for CyPath® Lung Test
Sep 18, 2024 8:00 am EDT Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
Aug 23, 2024 5:15 pm EDT bioAffinity Technologies CFO to Depart for New Opportunity; J. Michael Edwards to Return as Interim CFO
